These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 25022294)
1. Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. Mosha F; Ledwaba J; Ndugulile F; Ng'ang'a Z; Nsubuga P; Morris L; Kasubi M; Swai A; Vercauteren J; Vandamme AM J Infect Dev Ctries; 2014 Jul; 8(7):845-52. PubMed ID: 25022294 [TBL] [Abstract][Full Text] [Related]
2. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463 [TBL] [Abstract][Full Text] [Related]
3. Pre-treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring. Barabona G; Mahiti M; Masoud S; Mbelele P; Mgunya AS; Minja L; Sunguya B; Shigemi U; Matsuda M; Hachiya A; Iwatani Y; Lyamuya E; Ueno T J Antimicrob Chemother; 2019 Oct; 74(10):3016-3020. PubMed ID: 31273377 [TBL] [Abstract][Full Text] [Related]
4. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391 [TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
6. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120 [TBL] [Abstract][Full Text] [Related]
7. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. Johannessen A; Naman E; Kivuyo SL; Kasubi MJ; Holberg-Petersen M; Matee MI; Gundersen SG; Bruun JN BMC Infect Dis; 2009 Jul; 9():108. PubMed ID: 19583845 [TBL] [Abstract][Full Text] [Related]
8. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V; J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728 [TBL] [Abstract][Full Text] [Related]
9. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. Charpentier C; Gody JC; Mbitikon O; Moussa S; Matta M; Péré H; Fournier J; Longo Jde D; Bélec L AIDS Res Hum Retroviruses; 2012 Jan; 28(1):87-94. PubMed ID: 21599597 [TBL] [Abstract][Full Text] [Related]
10. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468 [TBL] [Abstract][Full Text] [Related]
11. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Maldonado F; Biot M; Roman F; Masquelier C; Anapenge M; Bastos R; Chuquela HC; Arendt V; Schmit JC; Zachariah R Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):607-12. PubMed ID: 18804251 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study. Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771 [TBL] [Abstract][Full Text] [Related]
13. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF; Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392 [TBL] [Abstract][Full Text] [Related]
14. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania. Ngarina M; Kilewo C; Karlsson K; Aboud S; Karlsson A; Marrone G; Leyna G; Ekström AM; Biberfeld G BMC Infect Dis; 2015 Apr; 15():175. PubMed ID: 25886277 [TBL] [Abstract][Full Text] [Related]
15. Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study. Lyatuu GW; Mwashemele SZ; Urrio R; Naburi H; Kashmir N; Machumi L; Kibao A; Sellah Z; Ulenga N; Orsini N; Biberfeld G; Kilewo C; Ekström AM Lancet HIV; 2021 May; 8(5):e256-e265. PubMed ID: 33581776 [TBL] [Abstract][Full Text] [Related]
16. High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam. Bwire GM; Aiko BG; Mosha IH; Kilapilo MS; Mangara A; Kazonda P; Swai JP; Swalehe O; Jordan MR; Vercauteren J; Sando D; Temba D; Shao A; Mauka W; Decouttere C; Vandaele N; Sangeda RZ; Killewo J; Vandamme AM Sci Rep; 2023 Nov; 13(1):20493. PubMed ID: 37993493 [TBL] [Abstract][Full Text] [Related]
17. A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy. Newman H; Breunig L; van Zyl G; Stich A; Preiser W J Clin Virol; 2014 Aug; 60(4):387-91. PubMed ID: 24929754 [TBL] [Abstract][Full Text] [Related]
18. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J; Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673 [TBL] [Abstract][Full Text] [Related]
19. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS). Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT; J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257 [TBL] [Abstract][Full Text] [Related]
20. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Somi GR; Kibuka T; Diallo K; Tuhuma T; Bennett DE; Yang C; Kagoma C; Lyamuya EF; Swai RO; Kassim S Antivir Ther; 2008; 13 Suppl 2():77-82. PubMed ID: 18575194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]